Novo Nordisk Seeks US and EU Approval for Sickle Cell Drug Etavopivat
Novo Nordisk announced US and European regulatory submissions on November 13, 2026, for etavopivat, an investigational once-daily oral treatment for sickle cell disease in adolescents and adults aged 12 years and older. The company submitted a New Drug Application to the US Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency, seeking approval for what it describes as a potential disease-modifying therapy. The submissions are requests for…